2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.
about
Consensus treatment plans for new-onset systemic juvenile idiopathic arthritisBiologic agents in juvenile spondyloarthropathiesEfficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trialsFinding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre studyTreatment of juvenile idiopathic arthritis: a revolution in carePrediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature reviewWhat does an adult rheumatologist need to know about juvenile idiopathic arthritis?Advances in the treatment of polyarticular juvenile idiopathic arthritisThe Future Is Now: Biologics for Non-Infectious Pediatric Anterior UveitisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentAn i2b2-based, generalizable, open source, self-scaling chronic disease registryGenome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis casesDynamic Changes, Cut-Off Points, Sensitivity, and Specificity of Laboratory Data to Differentiate Macrophage Activation Syndrome from Active Disease.Self-reported pain and disease symptoms persist in juvenile idiopathic arthritis despite treatment advances: an electronic diary study.2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening aMulticenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approachesEfficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFα drugs early in disease course.Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case seriesWhat are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of ChildrComplementary and alternative medicine use in adolescents with inflammatory bowel disease and juvenile idiopathic arthritis.Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the Phase 4 registry.Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis - epidemiology and management approachesEfficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.Intra-articular glucocorticoid injections in patients with juvenile idiopathic arthritis in a Singapore hospital.Indications for IVIG in rheumatic diseasesLipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.Current medical treatments for juvenile idiopathic arthritis.Do patients with juvenile idiopathic arthritis in clinical remission have evidence of persistent inflammation on 3T magnetic resonance imaging?Systemic arthritis in children: a review of clinical presentation and treatmentChildhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritisA Systematic Critical Appraisal of Clinical Practice Guidelines in Juvenile Idiopathic Arthritis Using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) InstrumentJuvenile spondyloarthritis.Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.A randomized study of local anesthesia for pain control during intra-articular corticosteroid injection in children with arthritis.Juvenile spondyloarthritis treatment recommendationsSocioeconomic costs and health-related quality of life in juvenile idiopathic arthritis: a cost-of-illness study in the United Kingdom.
P2860
Q24610145-B9CAB309-3812-4B80-981F-DE67D340F7EFQ26766263-887FB4D7-A1AA-4DD5-ADBF-53F8577412DCQ26775512-6947FE94-83ED-4112-967A-4A3D05A40ABFQ26786198-FD61615A-C815-429A-859E-7E692896F9CDQ26849497-FAD2530F-E4CB-4E17-89C5-32C1EFDED39DQ26991741-0DAF6ACD-3DF6-436D-8A67-18F6D2A814B6Q26995394-119901F8-8CA2-4A6A-99B7-9909DB8F9B13Q27001017-00A9C87E-DF47-4E3B-BBDF-A94479F42C8BQ27025862-FBAB9352-8289-415A-859E-FDC861ACB4FEQ28079246-1B20DCC7-4C93-4581-A1AE-2F45E0805ED7Q28709495-63E210DF-A847-4703-B057-B645C08A32E8Q30795448-4F556615-DA2A-4341-A1CF-EC8997695281Q30969802-7042251A-3514-4B93-A503-1F7DE8B95377Q33440560-BB411AC9-C23D-4DA5-BFC5-27DF5C4C62C3Q33613293-2395911D-9588-468D-A988-1FBE95AFB343Q33629843-408BCC17-DEBE-4D8D-BB49-738005073B22Q33659233-899D5CC0-3A4A-440C-B8E3-3FEF6F1718E1Q33692269-3871764E-FEA0-442C-BB95-88479901A280Q33712570-B4831CA7-BAB0-49B9-BBFB-A64124DECB58Q33765738-FE3951C5-57AF-4C17-9633-57AF4BEA7CE3Q33801499-C29F562F-3748-4DCE-AD63-869E047CCCA5Q33913947-B9686B6F-CD96-4481-BA77-541F87335ACBQ33936827-8A2D6C04-AC8D-4B2D-85A9-0CAEBF3A305DQ34169257-5EBE58A7-74A7-4B3A-A356-02CF8EAE8B44Q34434750-084ECD9B-FEDE-4530-8855-5DBB2BC5CBAAQ34646212-6DFFB548-2BDB-4B5C-A3E7-4AB437DE678DQ34929326-127A2419-2F72-48AA-A094-8DA876FEE0FBQ35102141-1EB82F27-D017-4A28-97A6-441D0B83235FQ35112757-B605242C-8795-4B52-AE7C-2195BC4CC4D7Q35147847-5EF42FFF-F88D-4F50-9EBD-DF44B0454FFBQ35294398-FDE35190-9ECE-4E92-820D-C972269C594CQ35431243-07C8CD1C-7957-45EE-AAE2-996A23C7898EQ35659928-750EAE7B-7C35-47C2-BCFA-BA793E1E325AQ35743755-6E2C8F9B-553A-49EC-ADDE-319E3F763296Q35769120-7A1875F3-0B89-4507-9398-D577338E6692Q35800954-4FACB448-89C2-418F-A200-38EF342692C7Q35870808-0270A742-7047-4DC7-A443-EC79563E71EAQ35997280-38F32852-208C-4B79-9C0F-BD8B33CA8A21Q36004879-09F05475-1AAB-4AC5-A9D1-8DACF4713084Q36092980-416E1DF2-F4A0-42F3-80E1-41844F25DDDA
P2860
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
2011 American College of Rheum ...... thritis and systemic features.
@ast
2011 American College of Rheum ...... thritis and systemic features.
@en
type
label
2011 American College of Rheum ...... thritis and systemic features.
@ast
2011 American College of Rheum ...... thritis and systemic features.
@en
prefLabel
2011 American College of Rheum ...... thritis and systemic features.
@ast
2011 American College of Rheum ...... thritis and systemic features.
@en
P2093
P2860
P356
P1476
2011 American College of Rheum ...... thritis and systemic features.
@en
P2093
Alberto Martini
C Egla Rabinovich
Daniel J Lovell
Esi Morgan DeWitt
Kenneth G Saag
Nivedita M Patkar
Norman T Ilowite
Randy Q Cron
Ronald M Laxer
Sue Tolleson-Rinehart
P2860
P304
P356
10.1002/ACR.20460
P577
2011-04-01T00:00:00Z